Business Description
Coloplast AS
NAICS : 334510
ISIN : DK0060448595
Share Class Description:
MEX:0QBO: Class BCompare
Compare
Traded in other countries / regions
COLO B.DenmarkCLPBY.USA0QBO.UKCBH.GermanyCOLO.AustriaCOLOB.Switzerland0QBO.Mexico IPO Date
2015-04-08Description
Coloplast is a leading global competitor in ostomy management and continence care. The firm designs, manufactures, and markets ostomy care systems, disposable containment devices, paste, powder, seals, and intermittent catheters for continence care. Coloplast also maintains a tertiary presence in the urology and woundcare markets, where it manufactures and markets penile implants, slings for incontinence and prolapse, and wound dressings. The company derives more than 60% of sales from Europe, 24% from other developed countries, and 17% from the rest of the world.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 0.04 | |||||
| Equity-to-Asset | 0.37 | |||||
| Debt-to-Equity | 1.26 | |||||
| Debt-to-EBITDA | 2.67 | |||||
| Interest Coverage | 9.05 | |||||
| Piotroski F-Score | 4/9 | |||||
| Altman Z-Score | 5.07 | |||||
| Beneish M-Score | -2.2 | |||||
| WACC vs ROIC | ||||||
Growth Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 9.7 | |||||
| 3-Year EBITDA Growth Rate | 4.5 | |||||
| 3-Year EPS without NRI Growth Rate | -1.5 | |||||
| 3-Year FCF Growth Rate | -26 | |||||
| 3-Year Book Growth Rate | 27.5 | |||||
| Future 3-5Y EPS without NRI Growth Rate | 14.61 | |||||
| Future 3-5Y Total Revenue Growth Rate | 8.4 |
Momentum Rank
10/10
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.02 | |||||
| Quick Ratio | 0.66 | |||||
| Cash Ratio | 0.08 | |||||
| Days Inventory | 149.57 | |||||
| Days Sales Outstanding | 61.73 | |||||
| Days Payable | 53.2 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Dividend Growth Rate | 5.3 | |||||
| 3-Year Average Share Buyback Ratio | -1.9 | |||||
| Shareholder Yield % | 1.41 |
Profitability Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 67.59 | |||||
| Operating Margin % | 26.96 | |||||
| Net Margin % | 18.69 | |||||
| FCF Margin % | 6.39 | |||||
| ROE % | 30.4 | |||||
| ROA % | 10.46 | |||||
| ROIC % | 12.4 | |||||
| ROC (Joel Greenblatt) % | 81.78 | |||||
| ROCE % | 21.64 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 35.32 | |||||
| Forward PE Ratio | 27.82 | |||||
| PE Ratio without NRI | 35.51 | |||||
| Shiller PE Ratio | 39.1 | |||||
| Price-to-Owner-Earnings | 43.46 | |||||
| PEG Ratio | 5.15 | |||||
| PS Ratio | 6.56 | |||||
| PB Ratio | 9.96 | |||||
| Price-to-Free-Cash-Flow | 122.35 | |||||
| Price-to-Operating-Cash-Flow | 63.46 | |||||
| EV-to-EBIT | 28.1 | |||||
| EV-to-Forward-EBIT | 28.8 | |||||
| EV-to-EBITDA | 23.83 | |||||
| EV-to-Forward-EBITDA | 25.27 | |||||
| EV-to-Revenue | 7.48 | |||||
| EV-to-Forward-Revenue | 8.44 | |||||
| EV-to-FCF | 141.25 | |||||
| Price-to-Projected-FCF | 3.36 | |||||
| Price-to-DCF (Earnings Based) | 2.62 | |||||
| Price-to-DCF (FCF Based) | 7.46 | |||||
| Price-to-Median-PS-Value | 0.8 | |||||
| Price-to-Peter-Lynch-Fair-Value | 5.36 | |||||
| Earnings Yield (Greenblatt) % | 3.56 | |||||
| FCF Yield % | 0.78 | |||||
| Forward Rate of Return (Yacktman) % | 8.53 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Coloplast AS Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil MXN) | 71,065.996 | ||
| EPS (TTM) (MXN) | 59.062 | ||
| Beta | 0.1 | ||
| Volatility % | 1.98 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (MXN) | 0 | ||
| 20-Day SMA (MXN) | 2082.59 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (MXN) | 2082.59 - 2082.59 | ||
| Shares Outstanding (Mil) | 225.34 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Coloplast AS Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Coloplast AS Stock Events
| Event | Date | Price(MXN) | ||
|---|---|---|---|---|
| No Event Data | ||||
Coloplast AS Frequently Asked Questions
What is Coloplast AS(MEX:0QBO)'s stock price today?
The current price of MEX:0QBO is MXN2082.59. The 52 week high of MEX:0QBO is MXN2082.59 and 52 week low is MXN2082.59.
When is next earnings date of Coloplast AS(MEX:0QBO)?
The next earnings date of Coloplast AS(MEX:0QBO) is 2025-02-04.
Does Coloplast AS(MEX:0QBO) pay dividends? If so, how much?
Coloplast AS(MEX:0QBO) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers